AstraZeneca: A Rare Compound Growth Opportunity In Biopharma

2025-12-10 10:26:49 ET

Introduction

AstraZeneca ( AZN ) is looking to be the first biopharma to throw off the cloak of cyclicality due to their work in optimizing the commercial and pipeline asset base. Despite being able to leverage experience and economies of scale, big pharma has traditionally failed to provide decent, predictable, SWAN-like compound growth. If the VanEck Pharmaceutical ETF PPH is any indicator, then long-term compounding growth is not a key trait of biopharma companies despite their strong pricing power and global networks. Much of the risk is due to the nature of drug patenting, as most drugs lose exclusivity within ten to 15 years of approval. AstraZeneca was a key case study of this pattern at work in the 2010s, as the loss of Arimidex, Seroquel, Nexium, and Crestor all lost exclusivity between 2010 and 2016....

Read the full article on Seeking Alpha

For further details see: